Diabesity Rounds

Dapagliflozin vs empagliflozin

Dapagliflozin and empagliflozin are the two most used SGLT2 inhibitors. Both are off patent in India. This page brings together our reports on each, and on studies that looked at both.

Studies that looked at both

None of our reports so far has covered a study of both. This list updates itself when one is published.

Dapagliflozin

Empagliflozin

No reports yet.

For registered medical practitioners. This page summarises published research and is not advice for individual patients. Last new report 18 October 2026.